CARDIOGEN 20 MG

Cardiogen 20 mg – Peptide Hubs

Cardiogen is a novel research peptide designed to promote cardiac tissue regeneration, enhance endothelial function, and support recovery after myocardial stress. The 20 mg lyophilized vial from Peptide Hubs delivers high-purity formulation for experimental applications in cardiovascular health, post-infarction repair, and vascular inflammation models.

What Is Cardiogen?

Cardiogen is modeled after natural peptides involved in cardiac repair signaling, particularly those that influence angiogenesis, fibrosis modulation, and cellular regeneration within cardiac muscle. It is being studied for its therapeutic potential in cases of heart failure, ischemia-reperfusion injury, and vascular damage induced by oxidative stress or metabolic dysfunction.

Mechanism of Action

Cardiogen is believed to activate pathways related to VEGF (vascular endothelial growth factor) and IGF-1, enhancing oxygen delivery, reducing tissue necrosis, and improving microvascular regeneration. Its ability to modulate pro-inflammatory cytokines and reduce scar tissue formation makes it a strong candidate for post-MI (myocardial infarction) research. See related analysis in this NIH article on peptide-based cardiovascular repair.

Applications in Research

Cardiogen 20 mg is used in studies exploring:

• Myocardial tissue regeneration
• Endothelial healing after ischemia
• Cardiac fibrosis reduction
• Enhanced angiogenesis in the heart and vasculature

Its potential extends to metabolic cardiology protocols, often in synergy with insulin-sensitizing agents or inflammation regulators. In some research setups, it's stacked with ARA-290 and BPC-157 for broader cardiovascular protection and recovery.

Suggested Experimental Use

• Dose: 10–20 mg per day
• Route: Subcutaneous injection (or intraperitoneal in animal models)
• Cycle: 7–28 days depending on severity of cardiac event or vascular insult

Stacking Options

For comprehensive heart and vascular recovery, Cardiogen is often combined in studies with:

• GHK-CU – reduces scar formation and supports angiogenesis
• Semax – for neurovascular recovery and anti-inflammatory action
• AOD 9604 – to aid metabolic recovery and fat mobilization post-cardiac trauma

Safety Profile

Cardiogen is not associated with androgenic, estrogenic, or hepatotoxic effects. It does not aromatize or elevate blood pressure and is considered well-tolerated in preclinical testing. Side effects are rare, limited to mild site irritation or temporary fatigue in some cases.

Legal Disclaimer

Cardiogen is not FDA-approved and is intended for research purposes only. It must not be used for human consumption. For ongoing studies and cardiovascular-related peptide protocols, visit ClinicalTrials.gov.

Frequently Asked Questions